Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

931988

registered interest
date	27/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Scientific Advisory Committee On Nutrition
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 4 June 2018 to Question 147850 on Scientific Advisory Committee on Nutrition, what need was identified (a) through horizon scanning and (b) at the request of government for each nutritional risk assessment carried out in each of the last five years.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	158195
answer	answer is ministerial correction date of answer 04/07/2018 answer text <p>The Scientific Advisory Committee on Nutrition (SACN) undertakes risk assessment activities in response to emerging evidence and/or views from other expert bodies; requests from the sponsoring departments; and/or horizon scanning. SACN last undertook horizon scanning at their meeting on 19 June 2018; the draft minutes of this meeting will be published on the SACN website by the end of July 2018.</p><p> </p><p>Nutritional needs identified by SACN over the last five years are numerous and are included in individual reports and position statements published on the SACN website:</p><p> </p><p><a href="https://www.gov.uk/government/groups/scientific-advisory-committee-on-nutrition#reports" target="_blank">https://www.gov.uk/government/groups/scientific-advisory-committee-on-nutrition#reports</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/07/2018 14:45:38 answering member 4067 label Biography information for Steve Brine
tabling member	1533 label Biography information for Dame Diana Johnson

931990

registered interest
date	27/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Scientific Advisory Committee On Nutrition
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 4 June 2018 to Question 147851, what recent assessment he has made of trends in the level of (a) malnutrition and (b) nutrition intake in the general population as set out in the National Diet and Nutrition Survey; and if he will make (i) it his policy to request advice from the Scientific Advisory Committee on Nutrition on how malnutrition in the general population can be tackled and (ii) a statement.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	158196
answer	answer is ministerial correction date of answer 04/07/2018 answer text <p>There are no current plans to request advice from the Scientific Advisory Committee on Nutrition on how malnutrition in the general population can be tackled.</p><p> </p><p>The National Diet and Nutrition Survey (NDNS) collects information on diet and nutrient intakes and nutritional status but does not assess the prevalence of malnutrition in the population. Malnutrition is a complex, multifactorial condition which develops over a period of time, and for which there is no single agreed medical definition. NDNS assesses an individual’s diet and nutritional status at a single point in time and cannot assess other factors associated with malnutrition such as weight loss, or malabsorption of nutrients due to disease. It is therefore not possible to classify individuals as malnourished solely from the data collected in NDNS.</p><p> </p><p>Data from the National Diet and Nutrition Survey collected between 2008 and 2016 shows that nutrient intakes have changed relatively little over this period with the exception of free sugars and salt.</p><p> </p><p>Mean intakes of free sugars for adults (19-64 years) and children (4-10 and 11-18 years) were significantly lower in 2014/16 than in 2008/10 though remained more than double the recommended maximum in all age groups. Mean salt intake in adults, assessed through urinary sodium surveys, was 11% lower in 2014 than in 2006 but also remained above the recommended maximum. Mean intakes of fibre in children were significantly lower in 2014/16 than in 2008/10 and were below the recommendation. There were no consistent trends in intakes of total or saturated fat, total carbohydrate, or for vitamins or minerals.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/07/2018 14:44:16 answering member 4067 label Biography information for Steve Brine
tabling member	1533 label Biography information for Dame Diana Johnson

931265

registered interest
date	26/06/2018
answering body	Foreign and Commonwealth Office
answering dept id	16
answering dept short name	Foreign and Commonwealth Office
answering dept sort name	Foreign and Commonwealth Office
hansard heading	Nicaragua: Human Rights
house id	1
legislature	25259 pref label House of Commons
question text	What recent assessment he has made of the human rights situation in Nicaragua.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	906056
answer	answer is ministerial correction date of answer 26/06/2018 answer text The Government remains deeply concerned by the reported human rights abuses and excessive use of force by security services. We condemn violence against peaceful protesters, particularly the use of live ammunition. The Nicaraguan Government must respect human rights and take responsibility for ending the violence. answering member constituency Rutland and Melton answering member printed Sir Alan Duncan question first answered 26/06/2018 15:06:59 answering member 343 label Biography information for Sir Alan Duncan
tabling member	1533 label Biography information for Dame Diana Johnson

928003

registered interest
date	20/06/2018
answering body	Northern Ireland Office
answering dept id	21
answering dept short name	Northern Ireland
answering dept sort name	Northern Ireland
hansard heading	Offences against the Person Act 1861: Northern Ireland
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Northern Ireland, whether she will exercise her power under section 26(2) of the Northern Ireland Act 1998 to repeal sections 58 and 59 of the Offences Against the Person Act 1861 in order to comply with the UK's international obligations under the United Nations Convention on the Elimination of All Forms of Discrimination against Women.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	155724
answer	answer is ministerial correction date of answer 27/06/2018 answer text <p>The Government has no plans to amend the law on abortion in either England and Wales or Northern Ireland.</p><p> </p><p>Abortion has always been a devolved matter in Northern Ireland. The Government's priority is therefore restoring devolved government, so that the people of Northern Ireland, and locally elected representatives, can decide what is right for Northern Ireland.</p><p> </p> answering member constituency Staffordshire Moorlands answering member printed Karen Bradley question first answered 27/06/2018 14:40:22 answering member 4110 label Biography information for Dame Karen Bradley
tabling member	1533 label Biography information for Dame Diana Johnson

928004

registered interest
date	20/06/2018
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Energy: Environment Protection
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what the timetable is for his Department to publish the Clean Energy Sector Deal.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	155725
answer	answer is ministerial correction date of answer 27/06/2018 answer text <p>Sector Deals are a new approach to the way Government works in partnership with industry to improve the productivity of their sector. Since the publication of the Industrial Strategy, four Deals have already been announced and there are more in discussion.</p><p> </p><p>Several sectors, including those in the clean energy sector, have expressed interest in a Sector Deal and we expect to progress with further Deals that best meet the expectations set out in the White Paper in due course.</p> answering member constituency Devizes answering member printed Claire Perry question first answered 27/06/2018 16:33:43 answering member 3974 label Biography information for Claire Perry
tabling member	1533 label Biography information for Dame Diana Johnson

926654

registered interest
date	18/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Haemophilia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps the Government is taking to increase the uptake of extended half life treatment by people with (a) haemophilia A and (b) haemophilia B.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	154637
answer	answer is ministerial correction date of answer 26/06/2018 answer text <p>Extended Half Life products are relatively new products for which data is maturing and is collected via the UK Haemophilia database. These products provide an appropriate treatment for some patients.</p><p> </p><p>NHS England, through the Commercial Medicines Unit (CMU), undertakes national tenders which allow all companies who produce plasma, recombinant and extended half-life products to submit prices to be included in the national pricing framework. The relative prices are used to determine commissioning access for all products, including extended half-life products.</p><p> </p><p>Through commissioning processes such as the Haemophilia Quality Dashboard, patient experience of treatment and its outcomes in relation to bleeds and joint scores is kept regularly under review. The opportunity to continuously improve the patient experience and value of treatment with similar or improved clinical outcomes is an area for further assessment based on new and emerging data.</p><p> </p><p>There are a number of new therapeutic agents for haemophilia, including extended half-life products, and many patients are being recruited to clinical trials or early access schemes for new products. When assessing tenders for haemophilia products, NHS England takes into account the clinical outcomes to be achieved, the data available on the products and the prices offered. The aim is to deliver access to a range of treatments to meet individual patient need whilst supporting the use of clinically appropriate lowest cost options to achieve the outcomes required. This process has delivered both access to new treatments and substantial savings. No review of the tendering process is planned.</p><p> </p><p>NHS England regularly reviews its tender framework for blood products to ensure a range of treatments are commissioned to meet individual patient and maximises the use of clinically appropriate lowest cost options to achieve the clinical outcomes required.</p><p> </p><p>An assessment of comparative uptake compared to the uptake in Ireland, Canada and the European Union has not been undertaken.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 154638 154639 154640 question first answered 26/06/2018 15:35:39 answering member 4067 label Biography information for Steve Brine
tabling member	1533 label Biography information for Dame Diana Johnson

926655

registered interest
date	18/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Haemophilia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether NHS England has made an assessment of (a) the potential merits of reducing the number of infusions of blood products, (b) improvements in health-related quality of life, (c) improved Haemophilia Joint Health scores and (d) reductions in Annual Bleeding Rates in decision-making on the procurement of haemophilia treatments; and if he will make an assessment of the effectiveness of NHS England’s tendering process for haemophilia treatment.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	154638
answer	answer is ministerial correction date of answer 26/06/2018 answer text <p>Extended Half Life products are relatively new products for which data is maturing and is collected via the UK Haemophilia database. These products provide an appropriate treatment for some patients.</p><p> </p><p>NHS England, through the Commercial Medicines Unit (CMU), undertakes national tenders which allow all companies who produce plasma, recombinant and extended half-life products to submit prices to be included in the national pricing framework. The relative prices are used to determine commissioning access for all products, including extended half-life products.</p><p> </p><p>Through commissioning processes such as the Haemophilia Quality Dashboard, patient experience of treatment and its outcomes in relation to bleeds and joint scores is kept regularly under review. The opportunity to continuously improve the patient experience and value of treatment with similar or improved clinical outcomes is an area for further assessment based on new and emerging data.</p><p> </p><p>There are a number of new therapeutic agents for haemophilia, including extended half-life products, and many patients are being recruited to clinical trials or early access schemes for new products. When assessing tenders for haemophilia products, NHS England takes into account the clinical outcomes to be achieved, the data available on the products and the prices offered. The aim is to deliver access to a range of treatments to meet individual patient need whilst supporting the use of clinically appropriate lowest cost options to achieve the outcomes required. This process has delivered both access to new treatments and substantial savings. No review of the tendering process is planned.</p><p> </p><p>NHS England regularly reviews its tender framework for blood products to ensure a range of treatments are commissioned to meet individual patient and maximises the use of clinically appropriate lowest cost options to achieve the clinical outcomes required.</p><p> </p><p>An assessment of comparative uptake compared to the uptake in Ireland, Canada and the European Union has not been undertaken.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 154637 154639 154640 question first answered 26/06/2018 15:35:39 answering member 4067 label Biography information for Steve Brine
tabling member	1533 label Biography information for Dame Diana Johnson

926656

registered interest
date	18/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Haemophilia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what comparative assessment the Government has made of the uptake in England of extended half life treatment for people with (a) haemophilia A and (b) haemophilia B with the uptake of that treatment in (i) Ireland, (ii) Canada and (iii) the EU.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	154639
answer	answer is ministerial correction date of answer 26/06/2018 answer text <p>Extended Half Life products are relatively new products for which data is maturing and is collected via the UK Haemophilia database. These products provide an appropriate treatment for some patients.</p><p> </p><p>NHS England, through the Commercial Medicines Unit (CMU), undertakes national tenders which allow all companies who produce plasma, recombinant and extended half-life products to submit prices to be included in the national pricing framework. The relative prices are used to determine commissioning access for all products, including extended half-life products.</p><p> </p><p>Through commissioning processes such as the Haemophilia Quality Dashboard, patient experience of treatment and its outcomes in relation to bleeds and joint scores is kept regularly under review. The opportunity to continuously improve the patient experience and value of treatment with similar or improved clinical outcomes is an area for further assessment based on new and emerging data.</p><p> </p><p>There are a number of new therapeutic agents for haemophilia, including extended half-life products, and many patients are being recruited to clinical trials or early access schemes for new products. When assessing tenders for haemophilia products, NHS England takes into account the clinical outcomes to be achieved, the data available on the products and the prices offered. The aim is to deliver access to a range of treatments to meet individual patient need whilst supporting the use of clinically appropriate lowest cost options to achieve the outcomes required. This process has delivered both access to new treatments and substantial savings. No review of the tendering process is planned.</p><p> </p><p>NHS England regularly reviews its tender framework for blood products to ensure a range of treatments are commissioned to meet individual patient and maximises the use of clinically appropriate lowest cost options to achieve the clinical outcomes required.</p><p> </p><p>An assessment of comparative uptake compared to the uptake in Ireland, Canada and the European Union has not been undertaken.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 154637 154638 154640 question first answered 26/06/2018 15:35:39 answering member 4067 label Biography information for Steve Brine
tabling member	1533 label Biography information for Dame Diana Johnson

926657

registered interest
date	18/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Haemophilia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, he will make it his policy to ensure that all eligible patients with (a) haemophilia A and (b) haemophilia B have access to extended half life blood treatments.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	154640
answer	answer is ministerial correction date of answer 26/06/2018 answer text <p>Extended Half Life products are relatively new products for which data is maturing and is collected via the UK Haemophilia database. These products provide an appropriate treatment for some patients.</p><p> </p><p>NHS England, through the Commercial Medicines Unit (CMU), undertakes national tenders which allow all companies who produce plasma, recombinant and extended half-life products to submit prices to be included in the national pricing framework. The relative prices are used to determine commissioning access for all products, including extended half-life products.</p><p> </p><p>Through commissioning processes such as the Haemophilia Quality Dashboard, patient experience of treatment and its outcomes in relation to bleeds and joint scores is kept regularly under review. The opportunity to continuously improve the patient experience and value of treatment with similar or improved clinical outcomes is an area for further assessment based on new and emerging data.</p><p> </p><p>There are a number of new therapeutic agents for haemophilia, including extended half-life products, and many patients are being recruited to clinical trials or early access schemes for new products. When assessing tenders for haemophilia products, NHS England takes into account the clinical outcomes to be achieved, the data available on the products and the prices offered. The aim is to deliver access to a range of treatments to meet individual patient need whilst supporting the use of clinically appropriate lowest cost options to achieve the outcomes required. This process has delivered both access to new treatments and substantial savings. No review of the tendering process is planned.</p><p> </p><p>NHS England regularly reviews its tender framework for blood products to ensure a range of treatments are commissioned to meet individual patient and maximises the use of clinically appropriate lowest cost options to achieve the clinical outcomes required.</p><p> </p><p>An assessment of comparative uptake compared to the uptake in Ireland, Canada and the European Union has not been undertaken.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 154637 154638 154639 question first answered 26/06/2018 15:35:39 answering member 4067 label Biography information for Steve Brine
tabling member	1533 label Biography information for Dame Diana Johnson

922049

registered interest
date	11/06/2018
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Domestic Abuse
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, what the timetable is for his Department to respond to it's consultation on the draft Domestic Violence and Abuse Bill; and what the timetable is for further steps to be taken in relation to that Bill.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	152095
answer	answer is ministerial correction date of answer 14/06/2018 answer text <p>On 8 March we launched a 12 week public consultation on proposals for a landmark domestic abuse Bill and a supporting package of practical action to transform the response to domestic abuse. The consultation closed on 31 May. Over 3,200 responses to the consultation were received. The responses to the consultation are being considered and a draft Bill will be published later this session.</p> answering member constituency Louth and Horncastle answering member printed Victoria Atkins question first answered 14/06/2018 16:28:07 answering member 4399 label Biography information for Victoria Atkins
tabling member	1533 label Biography information for Dame Diana Johnson